PROGENTOS THERAPEUTICS
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
PROGENTOS THERAPEUTICS
Industry:
Life Science Medical Therapeutics
Founded:
2023-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.progentos.com
Status:
Active
Total Funding:
65 M USD
Technology used in webpage:
CrUX Dataset CrUX Top 50m
Current Advisors List
Current Employees Featured
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Progentos Therapeutics
Longwood Fund
Longwood Fund investment in Series A - Progentos Therapeutics
Dolby Family Ventures
Dolby Family Ventures investment in Series A - Progentos Therapeutics
Alta Partners
Alta Partners investment in Series A - Progentos Therapeutics
Mission BioCapital
Mission BioCapital investment in Series A - Progentos Therapeutics
Official Site Inspections
http://www.progentos.com Semrush global rank: 14.3 M Semrush visits lastest month: 88
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Progentos Therapeutics"
Progentos - Regenerative Medicines for Chronic Diseases
Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.See details»
Progentos Therapeutics - Crunchbase Company Profile & Funding
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.See details»
Progentos Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Progentos Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Progentos Therapeutics - Overview, News & Similar companies
View Progentos Therapeutics (www.progentos.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Progentos Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Progentos Therapeutics Inc. of Watertown, MA. Get the latest business insights from Dun & Bradstreet.See details»
Progentos Therapeutics - Forbion
Progentos is developing a regenerative medicine for MS that can improve quality of life for patients. The company's scientists have identified and validated a novel target that generates …See details»
Progentos Therapeutics Closes $65 Million Series A Financing to …
WATERTOWN, Mass., May 20, 2024--Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple …See details»
Progentos Therapeutics - VentureRadar
"Progentos Therapeutics is a company focused on developing regenerative medicine for the treatment of multiple sclerosis (MS). Their innovative approach involves creating small …See details»
Progentos - 2025 Company Profile & Funding - Tracxn
May 8, 2025 Progentos is a series A company based in Watertown (United States), founded in 2023 by Sanjay Magavi and Chris Loose. It operates as a Developer of regenerative …See details»
Progentos Therapeutics Closes $65 Million Series A ... - Neuro …
May 20, 2024 The series A financing was led by Netherlands-based Forbion which was joined by Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures. “ We are truly …See details»
Progentos Therapeutics Closes $65M Series A Financing
May 21, 2024 Progentos Therapeutics announced that it has successfully raised $65 million in a Series A funding round. Progentos is a Boston-based startup with the mission of developing …See details»
Forbion leads $65 million Series A Financing of Progentos …
May 21, 2024 • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs • Progentos Therapeutics …See details»
Forbion-backed biotech Progentos debuts with $65M for MS drug
May 20, 2024 Forbion-backed biotech Progentos debuts with $65M for MS drug Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for …See details»
Progentos Therapeutics | Biotechnology | The Pharmaletter | The ...
Progentos launched in May 2024, announcing the closing of a $65 million series A round which will will enable the company to advance its MS program through human proof of concept …See details»
Chris Loose - Progentos
Chris Loose, CEO of Progentos Therapeutics. Developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.See details»
Progentos Therapeutics - Funding, Financials, Valuation & Investors
May 20, 2024 Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.See details»
Progentos Therapeutics Closes $65M Series A Financing - FinSMEs
May 20, 2024 Progentos Therapeutics, a Watertown, MA-based biotech company addressing the need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) …See details»
Progentos Therapeutics - Contacts, Employees, Board Members, …
Progentos Therapeutics has 3 current employee profiles, including Co-Founder and CEO Chris Loose. Progentos Therapeutics has 5 board members and advisors, including Dan Janney.See details»
Sanjay Magavi - Progentos
Sanjay Magavi, PhD, is Co-founder and the Chief Scientific Officer of Progentos Therapeutics. Previously, Sanjay led research efforts at Frequency Therapeutics as Vice president of …See details»
Equity firm Arctos approved as Chargers limited partner by NFL …
13 hours ago Dean Spanos and his family will retain control of the Chargers organization with approximately 61% of the franchise after Arctos buys an 8% stake in the team.See details»